Genzyme launches Sepracoat in UK:
This article was originally published in Clinica
Executive Summary
Genzyme launched its Sepracoat liquid barrier in the UK last week. Sepracoat is used during surgery to coat tissue and protect it from incidental trauma caused by drying, handling and contact with surgical instruments and materials. The viscous coating is made from a concentrated solution of hyaluronic acid, a substance which occurs naturally in the body. Sepracoat remains at the site of surgery for about 24 hours and is resorbed by the body in about five days. Genzyme, based in Cambridge, Massachusetts, is selling Sepracoat as an accompaniment to its Seprafilm physical barrier which is placed between tissues and organs after surgery to avoid adhesions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.